Goldman Sachs Group Inc. Has $78,000 Stock Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Goldman Sachs Group Inc. lowered its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 60.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,411 shares of the company’s stock after selling 75,819 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Autolus Therapeutics were worth $78,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of AUTL. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the 4th quarter worth about $26,000. Two Sigma Advisers LP raised its position in shares of Autolus Therapeutics by 4.8% in the fourth quarter. Two Sigma Advisers LP now owns 333,400 shares of the company’s stock valued at $783,000 after buying an additional 15,400 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Autolus Therapeutics by 48.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 386,001 shares of the company’s stock valued at $598,000 after buying an additional 126,021 shares in the last quarter. Aubrey Capital Management Ltd raised its position in shares of Autolus Therapeutics by 41.5% in the first quarter. Aubrey Capital Management Ltd now owns 119,998 shares of the company’s stock valued at $197,000 after buying an additional 35,176 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its position in shares of Autolus Therapeutics by 67.2% in the first quarter. Exchange Traded Concepts LLC now owns 69,993 shares of the company’s stock valued at $108,000 after buying an additional 28,127 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, July 21st. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Wells Fargo & Company dropped their price target on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $9.12.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $1.63 on Wednesday. The company has a 50 day simple moving average of $1.80 and a 200 day simple moving average of $1.79. The firm has a market cap of $433.81 million, a PE ratio of -1.94 and a beta of 1.87. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.11 and a 1 year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $12.92 million. As a group, research analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.